PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy
Abstract Progesterone-induced blocking factor 1 (PIBF1) is linked to pregnancy-induced immunity and tumor evasion of maternal immunity. PIBF1 is overexpressed in several cancers, including breast, cervical, and lymphoma. However, limited research is available on the role of PIBF1 in breast cancer an...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-10546-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226308939153408 |
|---|---|
| author | Eunju Shin Jewon Ryu Tae-Kyung Yoo Sae Byul Lee Jisun Kim Il Yong Chung Beom Seok Ko Hee Jeong Kim Jong Won Lee Jun Hyeong Lee Kyunggon Kim Sang-wook Lee Byung Ho Son |
| author_facet | Eunju Shin Jewon Ryu Tae-Kyung Yoo Sae Byul Lee Jisun Kim Il Yong Chung Beom Seok Ko Hee Jeong Kim Jong Won Lee Jun Hyeong Lee Kyunggon Kim Sang-wook Lee Byung Ho Son |
| author_sort | Eunju Shin |
| collection | DOAJ |
| description | Abstract Progesterone-induced blocking factor 1 (PIBF1) is linked to pregnancy-induced immunity and tumor evasion of maternal immunity. PIBF1 is overexpressed in several cancers, including breast, cervical, and lymphoma. However, limited research is available on the role of PIBF1 in breast cancer and its clinical outcomes. Therefore, we investigated the relationship between PIBF1 expression, prognosis, and its impact on chemotherapy response. Samples from 231 patients with high-risk triple-negative breast cancer (TNBC) who underwent surgery between 2008 and 2013 with lymph node metastasis and underwent taxane-based adjuvant chemotherapy were collected. Additionally, 238 non-TNBC patients matched to TNBC patients were selected. Immunohistochemical detection of the PIBF1 protein in tissues was conducted using a cut-off value of 3 (intensity plus proportion). Kaplan–Meier survival analysis assessed the probability of overall survival (OS). Using the clonogenic unit assay and knockdown methodologies in breast cancer cell lines, we examined the correlation between PIF1 expression and chemosensitivity. In a study of 469 patients with breast cancer, non-TNBC (n = 238) and TNBC (n = 231), those with PIBF1 expression manifested a lower histologic grade (p < 0.001), reduced p53 (p < 0.001) and decreased Ki-67 (p < 0.001) compared with their non-expressing counterparts. A significant difference in OS for patients with PIBF1 was observed, with non-TNBC patients showing superior outcomes. PIBF1 expression showed a relation with a better prognosis, and the statistical significance was borderline (hazard ratio = 0.44, 95% confidence interval = 0.18–1.11, p = 0.082). A correlation between PIBF1 expression in breast cancer cell lines (BT549, HCC70, BT20, and HS578T) and their sensitivity to paclitaxel was shown in vitro, with certain cell lines showing significant viability reductions and also resisting the treatment after PIBF1 knockdown. We observed a correlation between PIBF1 expression and improved prognosis in breast cancer patients with nodal metastasis undergo taxane-based chemotherapy, particularly in the non-TNBC cohort. We discerned a relationship between PIBF1 and chemosensitivity in our in vitro studies. These findings suggest the potential usefulness of PIBF1 as a predictive marker for guiding therapeutic approaches. |
| format | Article |
| id | doaj-art-d130f40fa459416e83014f2cd0b4575f |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-d130f40fa459416e83014f2cd0b4575f2025-08-24T11:30:02ZengNature PortfolioScientific Reports2045-23222025-08-0115111510.1038/s41598-025-10546-5PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapyEunju Shin0Jewon Ryu1Tae-Kyung Yoo2Sae Byul Lee3Jisun Kim4Il Yong Chung5Beom Seok Ko6Hee Jeong Kim7Jong Won Lee8Jun Hyeong Lee9Kyunggon Kim10Sang-wook Lee11Byung Ho Son12Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDepartment of Convergence Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterLa Sierra UniversityDepartment of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical CenterDepartment of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical CenterDivision of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical CenterAbstract Progesterone-induced blocking factor 1 (PIBF1) is linked to pregnancy-induced immunity and tumor evasion of maternal immunity. PIBF1 is overexpressed in several cancers, including breast, cervical, and lymphoma. However, limited research is available on the role of PIBF1 in breast cancer and its clinical outcomes. Therefore, we investigated the relationship between PIBF1 expression, prognosis, and its impact on chemotherapy response. Samples from 231 patients with high-risk triple-negative breast cancer (TNBC) who underwent surgery between 2008 and 2013 with lymph node metastasis and underwent taxane-based adjuvant chemotherapy were collected. Additionally, 238 non-TNBC patients matched to TNBC patients were selected. Immunohistochemical detection of the PIBF1 protein in tissues was conducted using a cut-off value of 3 (intensity plus proportion). Kaplan–Meier survival analysis assessed the probability of overall survival (OS). Using the clonogenic unit assay and knockdown methodologies in breast cancer cell lines, we examined the correlation between PIF1 expression and chemosensitivity. In a study of 469 patients with breast cancer, non-TNBC (n = 238) and TNBC (n = 231), those with PIBF1 expression manifested a lower histologic grade (p < 0.001), reduced p53 (p < 0.001) and decreased Ki-67 (p < 0.001) compared with their non-expressing counterparts. A significant difference in OS for patients with PIBF1 was observed, with non-TNBC patients showing superior outcomes. PIBF1 expression showed a relation with a better prognosis, and the statistical significance was borderline (hazard ratio = 0.44, 95% confidence interval = 0.18–1.11, p = 0.082). A correlation between PIBF1 expression in breast cancer cell lines (BT549, HCC70, BT20, and HS578T) and their sensitivity to paclitaxel was shown in vitro, with certain cell lines showing significant viability reductions and also resisting the treatment after PIBF1 knockdown. We observed a correlation between PIBF1 expression and improved prognosis in breast cancer patients with nodal metastasis undergo taxane-based chemotherapy, particularly in the non-TNBC cohort. We discerned a relationship between PIBF1 and chemosensitivity in our in vitro studies. These findings suggest the potential usefulness of PIBF1 as a predictive marker for guiding therapeutic approaches.https://doi.org/10.1038/s41598-025-10546-5Breast cancerProgesterone-induced blocking factorChemotherapyResponseIn vitro |
| spellingShingle | Eunju Shin Jewon Ryu Tae-Kyung Yoo Sae Byul Lee Jisun Kim Il Yong Chung Beom Seok Ko Hee Jeong Kim Jong Won Lee Jun Hyeong Lee Kyunggon Kim Sang-wook Lee Byung Ho Son PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy Scientific Reports Breast cancer Progesterone-induced blocking factor Chemotherapy Response In vitro |
| title | PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy |
| title_full | PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy |
| title_fullStr | PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy |
| title_full_unstemmed | PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy |
| title_short | PIBF1 expression and survival outcome in TNBC and Non-TNBC breast cancer patients with lymph node metastasis who undertaken chemotherapy |
| title_sort | pibf1 expression and survival outcome in tnbc and non tnbc breast cancer patients with lymph node metastasis who undertaken chemotherapy |
| topic | Breast cancer Progesterone-induced blocking factor Chemotherapy Response In vitro |
| url | https://doi.org/10.1038/s41598-025-10546-5 |
| work_keys_str_mv | AT eunjushin pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT jewonryu pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT taekyungyoo pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT saebyullee pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT jisunkim pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT ilyongchung pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT beomseokko pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT heejeongkim pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT jongwonlee pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT junhyeonglee pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT kyunggonkim pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT sangwooklee pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy AT byunghoson pibf1expressionandsurvivaloutcomeintnbcandnontnbcbreastcancerpatientswithlymphnodemetastasiswhoundertakenchemotherapy |